These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 10947491)
1. Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. Sculpher M; Palmer MK; Heyes A Pharmacoeconomics; 2000 Apr; 17(4):361-70. PubMed ID: 10947491 [TBL] [Abstract][Full Text] [Related]
2. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574 [TBL] [Abstract][Full Text] [Related]
3. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Ross P; Heron J; Cunningham D Eur J Cancer; 1996; 32A Suppl 5():S13-7. PubMed ID: 8958037 [TBL] [Abstract][Full Text] [Related]
4. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?]. Carnaghi C; Zucali P; Garassino I Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298 [TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. Groener MG; van Ineveld BM; Byttebier G; van Hout BA; Rutten FF Anticancer Drugs; 1999 Mar; 10(3):283-8. PubMed ID: 10327033 [TBL] [Abstract][Full Text] [Related]
6. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial]. Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535 [TBL] [Abstract][Full Text] [Related]
7. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada. Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416 [TBL] [Abstract][Full Text] [Related]
8. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. Cocconi G; Cunningham D; Van Cutsem E; Francois E; Gustavsson B; van Hazel G; Kerr D; Possinger K; Hietschold SM J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial. Borget I; Aupérin A; Pignon JP; Abbas M; Bouché O; Mousseau M; Raoul JL; Bedenne L; Cassan P; Clavero-Fabri MC; Stremsdoerfer N; Nasca S; Queuniet AM; Ducreux M; Oncology; 2006; 71(1-2):40-8. PubMed ID: 17344670 [TBL] [Abstract][Full Text] [Related]
10. Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics. Norum J; Balteskard L; Edna TH; Laino R; Wählby L; Rønning G J Chemother; 2002 Jun; 14(3):301-8. PubMed ID: 12120887 [TBL] [Abstract][Full Text] [Related]
11. Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. Ducreux M; Bouche O; Pignon JP; Mousseau M; Raoul JL; Cassan P; Leduc B; Berger C; Dunant A; Fournet J; Bedenne L; Oncology; 2006; 70(3):222-30. PubMed ID: 16816536 [TBL] [Abstract][Full Text] [Related]
12. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Cunningham D Br J Cancer; 1998; 77 Suppl 2(Suppl 2):15-21. PubMed ID: 9579851 [TBL] [Abstract][Full Text] [Related]
13. Raltitrexed-based chemotherapy for advanced colorectal cancer. Liu Y; Wu W; Hong W; Sun X; Wu J; Huang Q Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):219-25. PubMed ID: 24388340 [TBL] [Abstract][Full Text] [Related]
14. Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. Tse VC; Ng WT; Lee V; Lee AW; Chua DT; Chau J; McGhee SM BMC Cancer; 2011 Jul; 11():288. PubMed ID: 21740590 [TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for colorectal cancer. Goyle S; Maraveyas A Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107 [TBL] [Abstract][Full Text] [Related]
17. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Ducreux M; Van Cutsem E; Van Laethem JL; Gress TM; Jeziorski K; Rougier P; Wagener T; Anak O; Baron B; Nordlinger B; Eur J Cancer; 2005 Feb; 41(3):398-403. PubMed ID: 15691639 [TBL] [Abstract][Full Text] [Related]
18. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748 [No Abstract] [Full Text] [Related]
19. A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes. Young A; Topham C; Moore J; Turner J; Wardle J; Downes M; Evans V; Kay S Eur J Cancer Care (Engl); 1999 Sep; 8(3):154-61. PubMed ID: 10763646 [TBL] [Abstract][Full Text] [Related]
20. Conjoint analysis of a new Chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced Colorectal Cancer. Aristides M; Chen J; Schulz M; Williamson E; Clarke S; Grant K Pharmacoeconomics; 2002; 20(11):775-84. PubMed ID: 12201796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]